APO-FINGOLIMOD CAPSULE Canada - English - Health Canada

apo-fingolimod capsule

apotex inc - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents

MAR-FINGOLIMOD CAPSULE Canada - English - Health Canada

mar-fingolimod capsule

marcan pharmaceuticals inc - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents

SANDOZ FINGOLIMOD CAPSULE Canada - English - Health Canada

sandoz fingolimod capsule

sandoz canada incorporated - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents

ACH-FINGOLIMOD CAPSULE Canada - English - Health Canada

ach-fingolimod capsule

accord healthcare inc - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents

JAMP FINGOLIMOD CAPSULE Canada - English - Health Canada

jamp fingolimod capsule

jamp pharma corporation - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents

Gilenya Capsule 0.5mg Singapore - English - HSA (Health Sciences Authority)

gilenya capsule 0.5mg

novartis (singapore) pte ltd - fingolimod hcl 0.56 mg eqv fingolimod - capsule - 0.5mg - fingolimod hcl 0.56 mg eqv fingolimod 0.5mg

Gilenya European Union - English - EMA (European Medicines Agency)

gilenya

novartis europharm limited - fingolimod hydrochloride  - multiple sclerosis - immunosuppressants - gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).orpatients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

GILENYA CAPSULE 0.25mg Singapore - English - HSA (Health Sciences Authority)

gilenya capsule 0.25mg

novartis (singapore) pte ltd - fingolimod hcl 0.28mg eqv fingolimod - capsule - fingolimod hcl 0.28mg eqv fingolimod 0.25mg

Fingolimod Accord European Union - English - EMA (European Medicines Agency)

fingolimod accord

accord healthcare s.l.u. - fingolimod hydrochloride  - multiple sclerosis, relapsing-remitting - immunosuppressants, selective immunosuppressants - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapyorpatients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Fingolimod Genthon 0.5 mg, hard capsules Malta - English - Medicines Authority

fingolimod genthon 0.5 mg, hard capsules

genthon bv microweg 22, 6545 cm nijmegen, netherlands - fingolimod - hard capsule - fingolimod 0.5 mg - immunosuppressants